Eli Lilly and Company BDR (LILY34)
B3 B3 Primary Summary
LILY34 Chart
Eli Lilly and Company BDR Dividends
| LILY LILY34 In 2 weeks Estimated | Other | R$0.19 Per Share |
| LILY LILY34 2 months ago Paid | Other | R$0.19 Per Share |
| LILY LILY34 5 months ago Paid | Other | R$0.2 Per Share |
| LILY LILY34 8 months ago Paid | Other | R$0.18 Per Share |
| LILY LILY34 11 months ago Paid | Other | R$0.17 Per Share |
| LILY LILY34 14 May 2024 Paid | Other | R$0.16 Per Share |
Eli Lilly and Company BDR Earnings
| 7 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
| LILY LILY34 In 2 weeks Estimated | Other | R$0.19 Per Share |
| LILY LILY34 2 months ago Paid | Other | R$0.19 Per Share |
| LILY LILY34 5 months ago Paid | Other | R$0.2 Per Share |
| LILY LILY34 8 months ago Paid | Other | R$0.18 Per Share |
| LILY LILY34 11 months ago Paid | Other | R$0.17 Per Share |
| LILY LILY34 14 May 2024 Paid | Other | R$0.16 Per Share |
| 7 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
Eli Lilly and Company BDR (LILY34) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Eli Lilly and Company BDR ever had a stock split?
Eli Lilly and Company BDR Profile
| Drug Manufacturers - General Industry | Healthcare Sector | David A. Ricks CEO | B3 Exchange | BRLILYBDR006 ISIN |
| US Country | 47,000 Employees | 14 May 2025 Last Dividend | - Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
